Composition capable of decreasing uric acid and preparation thereof

A technology for reducing uric acid and composition, applied in the field of uric acid-lowering compositions and preparations thereof, can solve problems such as neutropenia, patient suffering, threat to health, etc., and achieve the effects of promoting uric acid excretion, good uric acid-lowering effect, and lowering uric acid value

Active Publication Date: 2016-03-16
BY HEALTH CO LTD
View PDF3 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these drugs have a good curative effect on the treatment of gout, they all show certain toxic and side effects in clinical practice. Among them, the adverse reactions of febuxostat include abnormal liver function, diarrhea, headache, joint-related signs and symptoms and muscle pain. Bone / connective tissue symptoms; allopurinol common adverse reactions such as rash, diarrhea, abdominal pain, low fever, transient transaminase elevation or neutropenia; colchicine is highly toxic, common nausea, vomiting, diarrhea, abdominal pain, gastrointestinal reactions, Hematuria, oliguria, direct inhibitory effect on bone marrow, causing agranulocytosis, aplastic anemia, etc.; benzbromarone can cause neutropenia; probenecid common gastrointestinal reactions, rash, fever and other adverse reactions, long-term The use of these drugs brings great pain to patients, threatens health and affects quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition capable of decreasing uric acid and preparation thereof
  • Composition capable of decreasing uric acid and preparation thereof
  • Composition capable of decreasing uric acid and preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1 uric acid lowering test

[0045] 1. Materials and methods

[0046] Experimental animals: SPF grade male SD rats, weighing 180±10 g, were provided by Beijing Speiford Experimental Animal Center (permit number: SYXK (Beijing) 2014-0037).

[0047] Test groups: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group and test group, with 10 rats in each group.

[0048] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.

[0049] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test substance, add an appropriate amo...

Embodiment 2

[0073] Embodiment 2 lowering uric acid test

[0074] 1. Materials and methods

[0075] Experimental animals: male SD rats with SPF grade, weighing 180±10g, provided by Beijing Speiford Experimental Animal Center, (permit number: SYXK (Beijing) 2014-0037)

[0076] Test groups: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group and test group, with 10 rats in each group.

[0077] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.

[0078] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test substance, add an appropriate amou...

Embodiment 3

[0102] Embodiment 3 lowering uric acid test

[0103] 1. Materials and methods

[0104] Experimental animals: male SD rats with SPF grade, weighing 180±10g, provided by Beijing Speiford Experimental Animal Center, (permit number: SYXK (Beijing) 2014-0037)

[0105] Test groups: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group and test group, with 10 rats in each group.

[0106] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.

[0107] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test substance, add an appropriate amou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of health products, especially to a composition capable of decreasing uric acid and a preparation thereof. The composition capable of decreasing uric acid comprises skipjack extract and traditional Chinese medicine extract. After combined usage of the skipjack extract and the traditional Chinese medicine extract, better uric acid decreasing effect is obtained under the condition of reduction in dosage.

Description

technical field [0001] The invention relates to the technical field of health products, in particular to a uric acid-lowering composition and its preparation. Background technique [0002] With the improvement of people's living standards and changes in eating habits, the incidence of hyperuricemia and gout in my country has been increasing year by year in recent years. Hyperuricemia is a disease in which blood uric acid exceeds the normal value due to purine metabolism disorder and / or uric acid excretion disorder, and it does not show any symptoms clinically. When the human body is in the condition of hyperuricemia for a long time, uric acid is precipitated in the joints, soft tissues, cartilage and kidneys in the form of sodium salt, causing human organ and tissue lesions, leading to gout, and causing serious complications, including gouty Arthritis, gouty nephropathy, gouty kidney stones, gouty heart disease, gouty hypertension, etc., patients have joint pain, renal coli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/185A61K36/23A61K36/28A61K36/53A61K36/537A61K36/68A61K36/808A61K36/90A61K36/896A61K36/9066A61K35/616A61P19/06A23L33/00A61K35/60
CPCA23V2002/00A61K9/2059A61K35/60A61K35/616A61K36/185A61K36/23A61K36/28A61K36/53A61K36/537A61K36/68A61K36/808A61K36/896A61K36/90A61K36/9066A61K2300/00A23V2200/30A23V2250/21A23V2250/2042
Inventor 汪玉芳黄远英殷光玲袁根良
Owner BY HEALTH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap